Amelioration of experimentally induced diabetic nephropathy and renal damage by nilotinib

Regulation of podocalyxin expression in the kidney of streptozotocin-induced diabetic rats with Chinese herbs (Yishen capsule)

(2013) Jingai Fang et al.   BMC Complementary and Alternative Medicine

Modulation of thioacetamide-induced liver fibrosis/cirrhosis by sildenafil treatment

(2013) Eman Said et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin

(2013) John Wong et al.   CANCER BIOLOGY & THERAPY

Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes

(2013) Patricia O Prada et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin

(2012) M. Hara et al.   DIABETOLOGIA

Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin

(2012) Yoshikiyo Ito et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Nilotinib protects the murine liver from ischemia/reperfusion injury

(2012) Lee M. Ocuin et al.   JOURNAL OF HEPATOLOGY

Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib

(2011) Yuqing Liu et al.   JOURNAL OF HEPATOLOGY

Nilotinib Attenuates Renal Injury and Prolongs Survival in Chronic Kidney Disease

(2011) M. Iyoda et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Toll-Like Receptor 4 Promotes Tubular Inflammation in Diabetic Nephropathy

(2011) M. Lin et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

(2011) Hagop M Kantarjian et al.   LANCET ONCOLOGY

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

(2010) Paul W. Manley et al.   BIOORGANIC & MEDICINAL CHEMISTRY

The Neural Stem/Progenitor Cell Marker Nestin Is Expressed in Proliferative Endothelial Cells, but Not in Mature Vasculature

(2010) Sayuri Suzuki et al.   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice

(2010) Nicole M Agostino et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies

(2009) J H W Distler et al.   ANNALS OF THE RHEUMATIC DISEASES

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

(2009) Paul W. Manley et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Proliferation of Immature Tumor Vessels Is a Novel Marker of Clinical Progression in Prostate Cancer

(2009) K. Gravdal et al.   CANCER RESEARCH

Diabetic nephropathy

(2009) Themis Zelmanovitz et al.   Diabetology & Metabolic Syndrome

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib

(2008) Elizabeth Day et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis

(2008) Alfiya Akhmetshina et al.   FASEB JOURNAL

TLR4 Signaling Mediates Inflammation and Tissue Injury in Nephrotoxicity

(2008) B. Zhang et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice

(2008) C. Louvet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Novel redox-dependent regulation of NOX5 by the tyrosine kinase c-Abl

(2007) Amina El Jamali et al.   FREE RADICAL BIOLOGY AND MEDICINE